INCY Incyte (INCY) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Services-commercial physical & biological research · CIK 0000879169
Form 144 · 9
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
483
13F, latest reported quarter
Conversions, 180 days
29
Codes C/M, not in net · $9.6M priced
What the filings say about INCY
Insiders, 180 days
-$20.4M net sold
6 sellers · 15% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-05-15
Planned sales (Form 144), 90 days
$15.0M
9 notices
Incyte insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, INCYTE CORP insiders sold a net $20.4M of stock across 166 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Sep 15, 2026.
- The trade is 1.4% of the 183,200 shares held after it.
- No other insider sold within 30 days.
- 483 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, Global Head of R&D CAGNONI PABLO J sold about $297.8K of INCY under a 10b5-1 plan on Oct 15, 2026; 483 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Aug 19, 2026.
- The trade is 4.7% of the 197,185 shares held after it.
- No other insider sold within 30 days.
- 483 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, Global Head of R&D CAGNONI PABLO J sold about $1.1M of INCY under a 10b5-1 plan on Sep 15, 2026; 483 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Aug 19, 2026.
- The trade is 7.6% of the 183,200 shares held after it.
- No other insider sold within 30 days.
- 483 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, Global Head of R&D CAGNONI PABLO J sold about $1.7M of INCY under a 10b5-1 plan on Sep 15, 2026; 483 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 12, 2026.
- The trade is 5.9% of the 183,200 shares held after it.
- 1 other insider sold within 30 days.
- 483 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, Global Head of R&D CAGNONI PABLO J sold about $1.4M of INCY under a 10b5-1 plan on Aug 19, 2026; 1 other insider sold within 30 days and 483 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 5, 2026.
- The trade is 5.6% of the 194,001 shares held after it.
- 3 other insiders sold within 30 days.
- 483 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, Global Head of R&D CAGNONI PABLO J sold about $1.3M of INCY on Aug 12, 2026; 3 other insiders sold within 30 days and 483 funds added in the latest 13F quarter.166 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$20.4M over 180 days
-$15.0M over 90 days
below 88% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
483 funds bought in last quarter
more than 97% of Pharma & Biotech
Revenue
+21.2% year over year
more than 67% of Pharma & Biotech
Margin
25.0% net margin
more than 89% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.9% of the float short (float per yahoo 2026-10-26) · 6.1 days to cover · settled 2026-09-30
more than 51% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Oct 19President, Global Head of R&D CAGNONI PABLO J sold $297.8K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Officer PABLO CAGNONI filed to sell $297.8K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch INCY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+31.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns INCY: institutional holders (13F)
13F holdings, latest reported quarter
30,762,330 sh
$3.5B
18,032,718 sh
$2.0B
11,957,326 sh
$1.4B
11,024,289 sh
$1.2B
9,722,336 sh
$1.1B
Congress trades in INCY
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-05-15 · disclosed 16 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
INCY planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
PABLO CAGNONI
Filed 2026-10-15
$297.8K
PABLO CAGNONI
Filed 2026-09-15
$2.8M
PABLO CAGNONI
Filed 2026-08-19
$1.4M
PABLO CAGNONI
Filed 2026-08-12
$1.3M
PABLO CAGNONI
Filed 2026-08-05
$1.3M
INCY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Baird Chautauqua Global Growth Fund
$19.8M position · as of 2026-06-30
4.4%
iShares Genomics Immunology and Healthcare ETF
$8.1M position · as of 2026-07-31
4.2%
AlphaCentric Life Sciences and Healthcare Fund
$1.6M position · as of 2026-06-30
3.5%
LIVE OAK HEALTH SCIENCES FUND
$1.9M position · as of 2026-07-31
3.3%
First Trust NYSE Arca Biotechnology Index Fund
$89.6M position · as of 2026-06-30
3.2%
Invesco Biotechnology & Genome ETF
$8.6M position · as of 2026-07-31
3.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
196 registered trials, 57 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
61
Phase 1
18 active
55
Phase 2
12 active
47
Phase 3
22 active
1
Phase 4
0 active
9
Not applicable
3 active
23
Multi-phase
2 active
What changed recently
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Car
2026-10-21 · Active Not Recruiting → Terminated · This was a strategic business decision. There were no safety concerns contributing to this decision.
Phase 2
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune C
2026-10-21 · Active Not Recruiting → Terminated · This was a strategic business decision. There were no safety concerns contributing to this decision.
Phase 2
A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Singl
2026-10-15 · Not Yet Recruiting → Active Not Recruiting
Phase 1
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of
2026-10-10 · Completion moved 2026-09-03 → 2026-09-08
Phase 1
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of
2026-10-10 · Recruiting → Completed
Phase 1
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participa
2026-10-01 · Active Not Recruiting → Completed
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Hervé Hoppenot
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$16.4M
$13.4M
$3.7M
-0%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $20.4M sold by insiders over 180 days, 483 funds added last quarter, $15.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
INCY financials
Revenue growth
+21.2%
XBRL, annual
Net margin
25.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.4B
four quarters, 2025-04-01 to 2026-03-31
Revenue, TTM INCY
| FY Dec 2025 | $5.1B |
| FY Dec 2024 | $4.2B |
| FY Dec 2023 | $3.7B |
| FY Dec 2022 | $3.4B |
| FY Dec 2021 | $3.0B |
| Mar 2026 | $1.3B |
| Dec 2025 | $1.5B |
| Sep 2025 | $1.4B |
| Jun 2025 | $1.2B |
| Mar 2025 | $1.1B |
| Dec 2024 | $1.2B |
| Sep 2024 | $1.1B |
| Jun 2024 | $1.0B |
At each fiscal year end
Single quarter
Net margin, TTM
+26.7%
net income over revenue, 2025-04-01 to 2026-03-31
Net margin, TTM INCY
| FY Dec 2025 | +25.0% |
| FY Dec 2024 | +0.8% |
| FY Dec 2023 | +16.2% |
| FY Dec 2022 | +10.0% |
| FY Dec 2021 | +31.8% |
| Mar 2026 | +23.8% |
| Dec 2025 | +19.9% |
| Sep 2025 | +31.1% |
| Jun 2025 | +33.3% |
| Mar 2025 | +15.0% |
| Dec 2024 | +17.1% |
| Sep 2024 | +9.4% |
| Jun 2024 | -42.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.5B
operating cash flow minus capex, 2025-04-01 to 2026-03-31
Free cash flow, TTM INCY
| FY Dec 2025 | $1.4B |
| FY Dec 2024 | $249.1M |
| FY Dec 2023 | $464.0M |
| FY Dec 2022 | $892.1M |
| FY Dec 2021 | $568.5M |
| Mar 2026 | $359.2M |
| Dec 2025 | $521.4M |
| Sep 2025 | $544.6M |
| Jun 2025 | $25.7M |
| Mar 2025 | $262.9M |
| Dec 2024 | $363.8M |
| Sep 2024 | $305.7M |
| Jun 2024 | -$629.7M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2019-09-30 (79 months older than the period end); equity 2026-03-31
Debt to equity INCY
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.01x |
| Jun 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
83.89x
TTM operating cash flow over long-term debt only, 2019-09-30 (79 months older than the period end)
Cash flow to debt INCY
| FY Dec 2025 | 78.18x |
| FY Dec 2024 | 18.55x |
| FY Dec 2023 | 27.46x |
| FY Dec 2022 | 53.65x |
| FY Dec 2021 | 41.45x |
| Mar 2026 | 83.89x |
| Dec 2025 | 78.18x |
| Sep 2025 | 69.22x |
| Jun 2025 | 55.47x |
| Mar 2025 | 21.16x |
| Dec 2024 | 18.55x |
| Sep 2024 | 5.63x |
| Jun 2024 | -3.38x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+30.8%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on equity INCY
| FY Dec 2025 | +29.9% |
| FY Dec 2024 | +0.8% |
| FY Dec 2023 | +12.5% |
| FY Dec 2022 | +8.4% |
| FY Dec 2021 | +29.7% |
| Mar 2026 | +30.8% |
| Dec 2025 | +29.9% |
| Sep 2025 | +30.4% |
| Jun 2025 | +24.3% |
| Mar 2025 | +0.5% |
| Dec 2024 | +0.8% |
| Sep 2024 | +0.8% |
| Jun 2024 | +2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+21.9%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on assets INCY
| FY Dec 2025 | +20.7% |
| FY Dec 2024 | +0.5% |
| FY Dec 2023 | +9.5% |
| FY Dec 2022 | +6.3% |
| FY Dec 2021 | +22.3% |
| Mar 2026 | +21.9% |
| Dec 2025 | +20.7% |
| Sep 2025 | +21.0% |
| Jun 2025 | +16.6% |
| Mar 2025 | +0.3% |
| Dec 2024 | +0.5% |
| Sep 2024 | +0.6% |
| Jun 2024 | +1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+66.3%
operating income after a 19.3% effective tax rate, over long-term debt only, 2019-09-30 (79 months older than the period end) plus average of 2025-03-31 and 2026-03-31 minus cash
Return on invested capital INCY
| FY Dec 2025 | +60.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +25.9% |
| FY Dec 2022 | +23.6% |
| FY Dec 2021 | n/a |
| Mar 2026 | +66.3% |
| Dec 2025 | +60.6% |
| Sep 2025 | +54.1% |
| Jun 2025 | +38.3% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+32.6%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
Return on capital employed INCY
| FY Dec 2025 | +32.8% |
| FY Dec 2024 | +1.3% |
| FY Dec 2023 | +12.1% |
| FY Dec 2022 | +13.2% |
| FY Dec 2021 | +16.7% |
| Mar 2026 | +32.6% |
| Dec 2025 | +32.8% |
| Sep 2025 | +34.8% |
| Jun 2025 | +30.1% |
| Mar 2025 | +3.6% |
| Dec 2024 | +1.3% |
| Sep 2024 | -1.2% |
| Jun 2024 | +0.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
16.34x
close 2026-10-23 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
P/E, trailing INCY
| FY Dec 2025 | 15.41x |
| FY Dec 2024 | 345.35x |
| FY Dec 2023 | 23.69x |
| FY Dec 2022 | 53.19x |
| FY Dec 2021 | 17.19x |
| Mar 2026 | 13.29x |
| Dec 2025 | 15.41x |
| Sep 2025 | 14.37x |
| Jun 2025 | 15.73x |
| Mar 2025 | 242.20x |
| Dec 2024 | 345.35x |
| Sep 2024 | 472.14x |
| Jun 2024 | 168.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$19.7B
market value at close 2026-10-23 on 2026-04-21 shares, plus long-term debt only, 2019-09-30 (79 months older than the period end), minus cash 2026-03-31
Enterprise value INCY
| FY Dec 2025 | $16.3B |
| FY Dec 2024 | $11.6B |
| FY Dec 2023 | $10.9B |
| FY Dec 2022 | $14.9B |
| FY Dec 2021 | $14.2B |
| Mar 2026 | $15.3B |
| Dec 2025 | $16.3B |
| Sep 2025 | $14.1B |
| Jun 2025 | $11.2B |
| Mar 2025 | $9.8B |
| Dec 2024 | $11.6B |
| Sep 2024 | $11.4B |
| Jun 2024 | $12.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield INCY
| FY Dec 2025 | +7.0% |
| FY Dec 2024 | +1.9% |
| FY Dec 2023 | +3.3% |
| FY Dec 2022 | +5.0% |
| FY Dec 2021 | +3.5% |
| Mar 2026 | +7.7% |
| Dec 2025 | +7.0% |
| Sep 2025 | +7.2% |
| Jun 2025 | +7.3% |
| Mar 2025 | +2.6% |
| Dec 2024 | +1.9% |
| Sep 2024 | +0.2% |
| Jun 2024 | -1.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.01x
P/E over trailing EPS growth of 2732%: four quarters to 2026-03-31 against the four to 2025-03-31
PEG, trailing INCY
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.31x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.01x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
| Jun 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $5.1B | $4.2B | $3.7B | $3.4B |
| Operating income | $1.5B | $61.4M | $620.5M | $579.4M |
| Net income | $1.3B | $32.6M | $597.6M | $340.7M |
| EPS (diluted) | 6.41 | 0.15 | 2.65 | 1.52 |
| Operating cash flow | $1.4B | $335.3M | $496.5M | $969.9M |
| Cash | $3.1B | $1.7B | $3.2B | $3.0B |
| Buybacks | $0 | $2.0B | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
INCY Stock Sonar score 6/7 axes
Find similar shapesCompareINCY ranks highest on profitability (94th percentile) and institutional and government (93rd), and lowest on insider conviction (6th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
INCY filings, in plain words
Are Incyte insiders buying or selling INCY?
In the 180 days to 2026-10-27, Incyte insiders were net sellers, a net $20.4M across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded INCY?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Rob Bresnahan dated 2025-05-15.
Are there planned insider sales of INCY?
Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $15.0M of stock; the latest, by PABLO CAGNONI, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-27, Incyte insiders were net sellers of INCY, a net $20.4M across purchases and sales reported on Form 4 by 6 sellers. 15% of the 26 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in INCY, none in the last year; the latest on record is a sale by Rob Bresnahan dated 2025-05-15. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $15.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
